Search results for "Tumor necrosis factor-alpha"

showing 10 items of 504 documents

Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis

2008

Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive reg…

AdultMalemedicine.medical_specialtyAnti-Inflammatory AgentsArthritisDermatologyAntibodies Monoclonal HumanizedSeverity of Illness IndexPsoriasis Psoriatic ArthritisPsoriatic arthritisPsoriasisSeverity of illnessSettore MED/35 - Malattie Cutanee E VenereemedicineAdalimumabHumansPsoriasisAdverse effectTumor Necrosis Factor-alphabusiness.industryArthritis PsoriaticAdalimumabAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRadiographyClinical trialTreatment OutcomeMonoclonalFemalebusinessmedicine.drugDermatologic Therapy
researchProduct

Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.

2002

Bacterial endotoxin activity is elevated in patients with decompensated chronic heart failure (HF) and acts as a potent stimulus for immune activation. We sought to determine whether endotoxin, at an activity level seen in vivo (around 0.6 EU/ml), is sufficient to stimulate the secretion of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha soluble receptor (sTNFR2) in ex vivo whole blood from patients with HF. We studied 15 patients with HF (aged 65 +/- 1.9 years, New York Heart Association class 2.1 +/- 0.3, left ventricular ejection fraction 31 +/- 5%; mean +/- SEM), of whom 5 had cardiac cachexia, and 7 healthy control subjects (59 +/- 5 years, p = NS). Reference endotoxin was added …

AdultMalemedicine.medical_specialtyCachexiaEnzyme-Linked Immunosorbent AssayReceptors Tumor Necrosis FactorCachexiaIn vivoInternal medicinemedicineHumansWhole bloodAgedHeart FailureEjection fractionbusiness.industryTumor Necrosis Factor-alphaVenous bloodMiddle Agedmedicine.diseaseEndotoxinsEndocrinologyHeart failureTumor necrosis factor alphaFemaleCardiology and Cardiovascular MedicinebusinessEx vivoThe American journal of cardiology
researchProduct

Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity

2021

Abstract Background and aims Obesity is a key contributing factor to incidental type 2 diabetes and cardiovascular disease. CXCR3 receptor and its ligands CXCL 10 and 11 are associated with atherosclerosis and cardiovascular disease. The aim of our study was to analyse the role of the CXCR3 ligands on insulin resistance (IR) and endothelial dysfunction in human obesity. Methods and results We have studied 45 obese patients (mean age 44 ± 6 years, body mass index 45 ± 9 kg/m2) who were selected for Roux-Y-gastric bypass surgery and 21 non obese control subjects with similar age and gender distribution. We measured by ELISA the circulating levels of the CXCR3 ligands interferon-γ inducible pr…

AdultMalemedicine.medical_specialtyChemokineReceptors CXCR3Type 2 diabetesCXCR3BiochemistryInsulin resistanceInternal medicineCell AdhesionLeukocytesmedicineHumansCXCL10CXCL11ObesityEndothelial dysfunctionCells CulturedbiologyTumor Necrosis Factor-alphabusiness.industryEndothelial CellsCell BiologyMiddle Agedmedicine.diseaseChemokine CXCL11Up-RegulationChemokine CXCL10EndocrinologyCase-Control Studiesbiology.proteinFemaleInsulin ResistanceCardiology and Cardiovascular MedicinebusinessBody mass indexSignal TransductionMicrovascular Research
researchProduct

Maximal Strength, Muscular Endurance and Inflammatory Biomarkers in Young Adult Men

2014

The aim was to study associations of maximal strength and muscular endurance with inflammatory biomarkers independent of cardiorespiratory fitness in those with and without abdominal obesity. 686 young healthy men participated (25±5 years). Maximal strength was measured via isometric testing using dynamo-meters to determine maximal strength index. Muscular endurance index consisted of push-ups, sit-ups and repeated squats. An indirect cycle ergometer test until exhaustion was used to estimate maximal aerobic capacity (VO2max). Participants were stratified according to those with (102 cm) and those without abdominal obesity (102 cm) based on waist circumference. Inflammatory factors (C-react…

AdultMalemedicine.medical_specialtyCross-sectional studyPhysical Therapy Sports Therapy and RehabilitationIsometric exercise030204 cardiovascular system & hematologyYoung Adult03 medical and health sciences0302 clinical medicinemedicineHumansOrthopedics and Sports MedicineMuscle Strength030212 general & internal medicineYoung adultAbdominal obesitybiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryC-reactive proteinVO2 maxCardiorespiratory fitnessmedicine.diseaseObesityC-Reactive ProteinCross-Sectional StudiesPhysical FitnessObesity AbdominalPhysical EndurancePhysical therapybiology.proteinWaist Circumferencemedicine.symptombusinessBiomarkersInternational Journal of Sports Medicine
researchProduct

The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

2018

Background The addition of an immunosuppressant (IM) after loss of response to anti-TNFα monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficacy and safety of this selective combination therapy in patients with IBD. Methods All consecutive patients with loss of response to anti-TNFα monotherapy despite an intensive dose optimization who added an IM from October 2014 to October 2016 were entered into a prospective database. Results Among 630 patients treated with anti-TNFα agents during the study period, 46 (7.3%) added an IM. A total of 31 patie…

AdultMalemedicine.medical_specialtyDatabases FactualCombination therapyGastroenterologyInflammatory bowel diseaseDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdalimumabHumansImmunology and AllergyProspective StudiesAdverse effectbiologyTumor Necrosis Factor-alphabusiness.industryRemission InductionC-reactive proteinAdalimumabGastroenterologyAntibodies MonoclonalMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseInfliximabGolimumabInfliximabDiscontinuationC-Reactive ProteinTreatment Outcome030220 oncology & carcinogenesisbiology.proteinDrug Therapy CombinationFemale030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugInflammatory Bowel Diseases
researchProduct

Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.

2017

Abstract Background Few studies investigated the role of mycophenolate mofetil in inflammatory bowel disease, and none of them had specifically focused on patients with previous multiple intolerances and/or nonresponses to conventional immunosuppressants and biologics. Aims To evaluate clinical benefit and tolerability profile of mycophenolate mofetil in patients with inflammatory bowel disease and limited treatment options. Methods All consecutive patients with previous multiple intolerances and/or nonresponses to immunosuppressants and biologics who started an off-label treatment with mycophenolate mofetil from January 2014 to February 2016 were entered in a prospectively maintained datab…

AdultMalemedicine.medical_specialtyDrug ResistanceKaplan-Meier EstimateMycophenolateInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineIntolerancesInternal medicineMedicineHumansIn patientEnzyme InhibitorsAgedCrohn's diseaseBiological ProductsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisDiscontinuationTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesisImmunology030211 gastroenterology & hepatologyFemalebusinessImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease

2018

OBJECTIVE The effect of pentoxifylline on Klotho levels in patients with type 2 diabetes mellitus with chronic kidney disease (CKD) was assessed in a post hoc analysis of the Pentoxifylline for Renoprotection in Diabetic Nephropathy (PREDIAN) trial. RESEARCH DESIGN AND METHODS Circulating and urinary tumor necrosis factor-α (TNF-α) and Klotho were measured before and after 1 year of pentoxifylline. The effect on Klotho expression was assessed in cultured renal tubular cells. RESULTS Pentoxifylline administration resulted in decreased serum and urinary TNF-α, whereas serum and urinary Klotho increased significantly. Changes in urinary Klotho, urinary TNF-α, and phosphorus were associated wi…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismUrinary system030232 urology & nephrologyRenal function030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesPentoxifyllineDiabetic nephropathyMice03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineAlbuminuriaAnimalsHumansMedicineDiabetic NephropathiesPentoxifyllineRenal Insufficiency ChronicKlotho ProteinsKlothoCells CulturedAgedGlucuronidaseAdvanced and Specialized NursingTumor Necrosis Factor-alphabusiness.industryKidney metabolismMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsKidney TubulesEndocrinologyDiabetes Mellitus Type 2AlbuminuriaFemalemedicine.symptombusinessFollow-Up StudiesGlomerular Filtration RateKidney diseasemedicine.drugDiabetes Care
researchProduct

Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk

2012

BACKGROUND Oxidative and inflammatory stresses are involved in the pathogenesis of atherosclerosis. The consumption of fruit and vegetables is associated with improved health and reduced cardiovascular risk. Red oranges have a high content of antioxidant and antiinflammatory substances, but there is a paucity of data concerning their effects on cardiovascular biomarkers in subjects with increased cardiovascular risk. OBJECTIVE We investigated the effect of red orange juice intake on endothelial function, oxidative stress, and markers of inflammation in subjects with increased cardiovascular risk. DESIGN Nineteen nondiabetic subjects with increased cardiovascular risk (aged 27-56 y) were inc…

AdultMalemedicine.medical_specialtyEndotheliumAnti-Inflammatory AgentsMedicine (miscellaneous)Inflammationmedicine.disease_causePlaceboAntioxidantsBeveragesYoung AdultRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineBody Fat DistributionHumansSingle-Blind MethodEndotheliumSettore MED/49 - Scienze Tecniche Dietetiche Applicateendothelial function cardiovascular risk red oranges inflammation FMDAgedInflammationOrange juiceCross-Over StudiesNutrition and DieteticsbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseCrossover studyOxidative StressC-Reactive ProteinEndocrinologymedicine.anatomical_structureCardiovascular DiseasesFruitbiology.proteinFemalemedicine.symptombusinessBiomarkersOxidative stressCitrus sinensis
researchProduct

Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alph…

2003

Ageing is associated with chronic, low grade inflammatory activity leading to long term tissue damage, and systemic chronic inflammation has been found to be related to mortality risk from all causes in older persons.1 Also, the genetic constitution of the organism interacting with systemic inflammation may cause defined organ specific illnesses. Thus, age related diseases such as Alzheimer’s disease (AD), Parkinson’s disease, atherosclerosis, type 2 diabetes, sarcopenia, and osteoporosis, are initiated or worsened by systemic inflammation, suggesting the critical importance of unregulated systemic inflammation in the shortening of survival in humans.1–3 Accordingly, proinflammatory cytokin…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentDNA Mutational AnalysisLongevityInflammationSingle-nucleotide polymorphismBiologySystemic inflammationPolymorphism Single NucleotideProinflammatory cytokineGene FrequencyInternal medicineGeneticsmedicineHumansAllelePromoter Regions GeneticGenetics (clinical)AgedGeneticsAged 80 and overInflammationTumor Necrosis Factor-alphaAge FactorsDNAMiddle AgedInterleukin-10Interleukin 10CytokineEndocrinologyImmunologyFemalemedicine.symptomCentenarianLetter to JMGJournal of medical genetics
researchProduct

A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity.

2001

The 8.1 ancestral haplotype (AH) is a common Caucasoid haplotype carried by most people who type for HLA-B8,DR3. It seems unique in its association with a wide range of immunopathologic diseases. Healthy subjects bearing this haplotype demonstrate several alterations of immune response. This article will focus on the identification of the mechanism(s) of disease susceptibility of 8.1 AH. In 13 carriers of 8.1 AH, and 43 negative patients, enzyme immune assays serum levels of tumor necrosis factor (TNF)-alpha, soluble endothelial leukocyte adhesion molecule-1 (sELAM-1), cortisol, and interleukin(IL)-10 were determined. In addition, quantification of cytokine produced in vitro after mitogen s…

AdultMalemedicine.medical_specialtyHydrocortisonemedicine.medical_treatmentImmunologyHLA-DR3Biologymedicine.disease_causeAutoimmunityAutoimmune DiseasesHLA-B8 AntigenImmune systemHLA-DR3 AntigenInternal medicinemedicineImmunology and AllergyHumansGenetic Predisposition to DiseaseCells CulturedTumor Necrosis Factor-alphaHaplotypeInterleukinGeneral MedicineMiddle AgedInterleukin-10Interleukin 10EndocrinologyCytokineHaplotypesImmunologyTumor necrosis factor alphaFemaleE-SelectinHuman immunology
researchProduct